Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shervin Assassi

Showing results (101-110 of 238) with videos related to

Pageof 24
Sort By:
Annals of the Rheumatic Diseases|September 26, 2009
Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosisPravitt Gourh, Frank C Arnett, Filemon K Tan, et al.
Arthritis Care & Research|June 1, 2026
The Gut-Heart Axis in Systemic Sclerosis: Evidence from the GENISOS cohortFrancesca R Di Ciommo, Ashish P Balar, Aidan K Strother, et al.
The Journal of Allergy and Clinical Immunology|November 23, 2016
Large-scale gene expression profiling reveals distinct type 2 inflammatory patterns in chronic rhinosinusitis subtypesMatthew A Tyler, Chris B Russell, Dirk E Smith, et al.
The Journal of Rheumatology|September 3, 2009
Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patientsShervin Assassi, Marvin J Fritzler, Frank C Arnett, et al.
ACR Open Rheumatology|January 20, 2022
The Effect of Anti-Scl-70 Antibody Determination Method on Its Predictive Significance for Interstitial Lung Disease Progression in Systemic SclerosisBochra Jandali, Gloria A Salazar, Marie Hudson, et al.
Annals of the Rheumatic Diseases|April 30, 2026
Efficacy and safety of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis in the FIBRONEER-ILD trialAnna-Maria Hoffmann-Vold, Shervin Assassi, Vincent Cottin, et al.
Arthritis and Rheumatism|July 31, 2013
Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosisShervin Assassi, Minghua Wu, Filemon K Tan, et al.
The Lancet. Rheumatology|September 25, 2023
Sex differences in clinical outcomes and biological profiles in systemic sclerosis-associated interstitial lung disease: a post-hoc analysis of two randomised controlled trialsElizabeth R Volkmann, Donald P Tashkin, Richard Silver, et al.
The Journal of Investigative Dermatology|December 26, 2023
Fibroblast Subpopulations in Systemic Sclerosis: Functional Implications of Individual Subpopulations and Correlations with Clinical FeaturesHonglin Zhu, Hui Luo, Brian Skaug, et al.
Arthritis Research & Therapy|January 1, 2017
Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung diseaseElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.
Pageof 24

Showing results (101-110 of 238) with videos related to

Sort By:
Pageof 24
Annals of the Rheumatic Diseases|September 26, 2009
Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosisPravitt Gourh, Frank C Arnett, Filemon K Tan, et al.
Arthritis Care & Research|June 1, 2026
The Gut-Heart Axis in Systemic Sclerosis: Evidence from the GENISOS cohortFrancesca R Di Ciommo, Ashish P Balar, Aidan K Strother, et al.
The Journal of Allergy and Clinical Immunology|November 23, 2016
Large-scale gene expression profiling reveals distinct type 2 inflammatory patterns in chronic rhinosinusitis subtypesMatthew A Tyler, Chris B Russell, Dirk E Smith, et al.
The Journal of Rheumatology|September 3, 2009
Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patientsShervin Assassi, Marvin J Fritzler, Frank C Arnett, et al.
ACR Open Rheumatology|January 20, 2022
The Effect of Anti-Scl-70 Antibody Determination Method on Its Predictive Significance for Interstitial Lung Disease Progression in Systemic SclerosisBochra Jandali, Gloria A Salazar, Marie Hudson, et al.
Annals of the Rheumatic Diseases|April 30, 2026
Efficacy and safety of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis in the FIBRONEER-ILD trialAnna-Maria Hoffmann-Vold, Shervin Assassi, Vincent Cottin, et al.
Arthritis and Rheumatism|July 31, 2013
Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosisShervin Assassi, Minghua Wu, Filemon K Tan, et al.
The Lancet. Rheumatology|September 25, 2023
Sex differences in clinical outcomes and biological profiles in systemic sclerosis-associated interstitial lung disease: a post-hoc analysis of two randomised controlled trialsElizabeth R Volkmann, Donald P Tashkin, Richard Silver, et al.
The Journal of Investigative Dermatology|December 26, 2023
Fibroblast Subpopulations in Systemic Sclerosis: Functional Implications of Individual Subpopulations and Correlations with Clinical FeaturesHonglin Zhu, Hui Luo, Brian Skaug, et al.
Arthritis Research & Therapy|January 1, 2017
Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung diseaseElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.
Pageof 24